NIH grant funds Missouri center's botanicals study
This article was originally published in The Tan Sheet
Executive Summary
The University of Missouri launches a national center to lead interdisciplinary and collaborative research on botanical dietary supplements with a $7.6 million, five-year National Institutes of Health grant. The university's Center for Botanical Interaction Studies will focus on the capabilities of garlic, elderberry, soy and other botanicals to help prevent stroke and prostate cancer and improve resistance to infectious diseases. Grace Sun, professor of biochemistry, pathology and anatomical sciences and a member of the university's Interdisciplinary Neuroscience Program, will lead a team of more than 20 scientists in studying how the botanicals use antioxidant properties to protect people from disease. The grant is from the NIH Office of Dietary Supplements' Botanical Research Centers Program (1"The Tan Sheet" Sept. 6, 2010, In Brief)
You may also be interested in...
Researchers evaluate botanicals' impact on menopause
A $7.4 million, five-year grant by the National Institutes of Health supports the University of Illinois at Chicago College of Pharmacy's research into the palliative effects of botanical dietary supplements, including black cohosh, licorice and hops, on menopausal symptoms. Norman Farnsworth, director of UIC's Program for Collaborative Research in Pharmaceutical Sciences, will lead the research to assess how multi-component mixtures work together, how they are absorbed, distributed and eliminated by the body and how they affect chemical and physical processes within the body, the college announces Sept. 1. Researchers also will study how the mixtures interact with drugs and impact women's estrogenic hormones. The grant is the third under the Botanical Research Centers Program, which was started after NIH's Office of Dietary Supplements received funding in 1999 to develop a botanicals initiative
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.